After Avandia, FDA Is Urged To Create "Emergency Response" Plan For Reassessing Drugs' Safety
This article was originally published in The Pink Sheet Daily
House Appropriations Subcommittee hearing offers forum for agency critics.
You may also be interested in...
Sponsors will get another look in July at how FDA interprets guidance for assessing the cardiovascular risk of diabetes drugs in clinical trials. The venue will be a meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees
Grassley Wants An Rx Safety Reorganization; Can FDA Keep Him At Bay Again? Congressional Avandia Investigation Reopens Door On Splitting CDER
Renewed congressional interest in a separate drug safety center at FDA is a likely off-shoot of a Senate Finance Committee report that questions GlaxoSmithKline's handling of cardiovascular safety issues surrounding Avandia
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.